Munich Cancer Registry



- ► Incidence and Mortality
- Selection Matrix
- Homepage
- Deutsch

ICD-10 C14: Other oral and pharynx cancer



Survival

Munich Cancer Registry Cancer Registry Bavaria - Upper Bavaria Regional Center at Klinikum Grosshadern/IBE Marchioninistr. 15 Munich, 81377 Germany

https://www.tumorregister-muenchen.de/en

https://www.tumorregister-muenchen.de/en/facts/surv/sC14_E-ICD-10-C14-Other-oral-and-pharynx-cancer-survival.pdf

Index of figures and tables

| Fig./Tb | ol. | Page |
|---------|---|------|
| 1a | Relative survival by period of diagnosis (chart) | 3 |
| 1b | Survival by period of diagnosis (table) | 3 |
| 2a | Survival by sex (chart) | 4 |
| 2b | Survival by sex (table) | 4 |
| 3a | Relative survival by age category (chart) | 5 |
| 3b | Survival by age category (table) | 5 |
| 5a | Time to first progression (chart) | 6 |
| 5b | Time to first progression (table) | 6 |
| 5c | Observed post-progression survival (chart) | 8 |
| 5d | Observed post-progression survival (table) | 8 |
| 5e | Observed post-progression survival by period of progression (chart) | 9 |
| 5f | Observed post-progression survival by period of progression (table) | 9 |



Figure 1a. Relative survival of patients with other oral and pharynx cancer by period of diagnosis. Included in the evaluation are 1,231 cases diagnosed between 1998 and 2020.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 2000 to 2018, and are represented by colored diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided populationbased statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

| I | Period of diagnosis | | | |
|--------|---------------------|--------|--------|--------|
| | 1998-2006 | | 2007+ | |
| | n=5 | 510 | n=721 | |
| Years | obs. % | rel. % | obs. % | rel. % |
| 0 | 100.0 | 100.0 | 100.0 | 100.0 |
| 1 | 74.3 | 75.3 | 79.7 | 80.7 |
| 2 | 56.3 | 57.8 | 64.8 | 66.7 |
| 3 | 46.2 | 48.0 | 55.8 | 58.3 |
| 4 | 41.0 | 43.1 | 49.4 | 52.3 |
| 5 | 37.0 | 39.6 | 45.9 | 49.7 |
| 6 | 33.7 | 36.6 | 41.5 | 45.6 |
| 7 | 31.3 | 34.5 | 37.0 | 41.4 |
| 8 | 30.1 | 33.5 | 35.8 | 40.8 |
| 9 | 25.4 | 28.8 | 32.5 | 37.9 |
| 10 | 23.1 | 26.5 | 30.2 | 35.9 |
| Median | 2.6 | | 3.9 | |

Table 1b. Observed (obs.) and relative (rel.) survival of patients with other oral and pharynx cancer by period of diagnosis for period 1998-2020 (N=1,231).




Figure 2a. Survival of patients with other oral and pharynx cancer by sex. Included in the evaluation are 1,231 cases diagnosed between 1998 and 2020.

| Sex | | | | | |
|--------|--------|--------|--------|--------|---|
| | Male | | Fen | nale | |
| | n=965 | | n=2 | 266 | |
| Years | obs. % | rel. % | obs. % | rel. % | |
| 0 | 100.0 | 100.0 | 100.0 | 100.0 | - |
| 1 | 75.9 | 77.0 | 82.9 | 83.7 | |
| 2 | 58.9 | 60.7 | 69.5 | 71.3 | |
| 3 | 49.7 | 51.9 | 59.3 | 61.5 | |
| 4 | 43.8 | 46.4 | 53.4 | 56.0 | |
| 5 | 39.9 | 43.0 | 50.3 | 53.8 | |
| 6 | 36.2 | 39.7 | 45.5 | 49.3 | |
| 7 | 32.9 | 36.6 | 41.3 | 45.8 | |
| 8 | 32.1 | 36.3 | 38.6 | 43.3 | |
| 9 | 28.2 | 32.6 | 32.7 | 37.7 | |
| 10 | 26.4 | 31.0 | 28.1 | 32.7 | |
| 11 | 23.6 | 28.2 | 25.8 | 30.7 | |
| 12 | 22.4 | 27.3 | 25.0 | 29.4 | |
| 13 | 19.9 | 24.4 | | | |
| 14 | 18.2 | 22.8 | | | |
| 15 | 16.5 | 21.1 | | | |
| Median | 3.0 | | 5.2 | 7 | - |
| | | | | | |

Table 2b. Observed (obs.) and relative (rel.) survival of patients with other oral and pharynx cancer by sex for period 1998-2020 (N=1,231).





Figure 3a. Relative survival of patients with other oral and pharynx cancer by age category. Included in the evaluation are 1,231 cases diagnosed between 1998 and 2020.

| | Age category | | | | | | | |
|--------|--------------|--------|-----------|--------|-----------|--------|---------|--------|
| | 0-49 | yrs | 50-59 yrs | | 60-69 yrs | | 70+ yrs | |
| | n=1 | 85 | n=457 | | n=390 | | n=199 | |
| Years | obs. % | rel. % | obs. % | rel. % | obs. % | rel. % | obs. % | rel. % |
| 0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| 1 | 82.6 | 82.5 | 78.3 | 78.6 | 76.8 | 77.8 | 71.6 | 75.0 |
| 2 | 67.3 | 67.2 | 61.5 | 62.3 | 60.4 | 62.1 | 56.5 | 61.8 |
| 3 | 57.9 | 58.1 | 51.7 | 52.7 | 50.5 | 52.7 | 48.4 | 55.5 |
| 4 | 52.9 | 53.3 | 47.0 | 47.9 | 43.2 | 45.8 | 41.6 | 50.2 |
| 5 | 49.4 | 50.2 | 43.9 | 45.3 | 39.3 | 42.3 | 36.3 | 46.6 |
| 6 | 47.1 | 48.0 | 38.5 | 40.1 | 36.0 | 39.5 | 33.1 | 44.7 |
| 7 | 45.3 | 46.2 | 35.2 | 36.9 | 32.3 | 36.4 | 27.5 | 39.7 |
| 8 | 45.3 | 46.1 | 33.1 | 35.1 | 31.9 | 36.3 | 25.3 | 38.8 |
| 9 | 43.2 | 44.5 | 28.7 | 31.0 | 26.9 | 31.5 | 19.8 | 32.9 |
| 10 | 40.4 | 41.8 | 28.7 | 31.0 | 21.4 | 25.7 | | |
| Median | 5.0 | | 3.1 | | 3.1 | | 2.9 | |
| | | | | | | | | |

Table 3b. Observed (obs.) and relative (rel.) survival of patients with other oral and pharynx cancer by age category for period 1998-2020 (N=1,231).






Figure 5a. Time to first progression of 1,230 patients with other oral and pharynx cancer diagnosed between 1998 and 2020 (in solid cancers M0 only) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting.

| Type of progression | | | | | | | | | |
|---------------------|---------------|---------------------|-----------------------|-------------------------|--------------------|----------------------|-------------------------------|--|--|
| | Any type (CI) | Any type (1- KM) | Local relapse (CI) | Local relapse (1-KM) | Lymph node (CI) | Lymph node (1-KM) | Distant metastasis (CI) | | |
| N | 1,181 | 1,181 | 1,230 | 1,230 | 1,230 | 1,230 | 1,181 | | |
| Events | 685 | 685 | 211 | 211 | 79 | 79 | 267 | | |
| compet. | 173 | | 648 | | 761 | | 528 | | |
| Years | % | % | % | % | % | % | % | | |
| 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | |
| 1 | 32.7 | 33.4 | 7.2 | 8.5 | 3.5 | 4.1 | 9.0 | | |
| 2 | 45.8 | 47.2 | 12.7 | 16.0 | 5.4 | 6.8 | 16.2 | | |
| 3 | 51.2 | 53.2 | 14.4 | 18.8 | 5.7 | 7.3 | 20.3 | | |
| 4 | 54.4 | 56.8 | 15.5 | 20.7 | 5.9 | 7.6 | 21.3 | | |
| 5 | 55.7 | 58.3 | 16.3 | 22.3 | 6.1 | 8.2 | 22.2 | | |
| 6 | 56.9 | 59.8 | 16.7 | 23.1 | 6.2 | 8.5 | 22.5 | | |
| 7 | 58.0 | 61.2 | 17.2 | 24.3 | 6.3 | 8.8 | 22.7 | | |
| 8 | 58.6 | 62.1 | 17.5 | 24.9 | 6.3 | 8.8 | 23.0 | | |
| 9 | 59.7 | 63.5 | 17.7 | 25.5 | 6.6 | 9.6 | 23.5 | | |
| 10 | 60.2 | 64.4 | 18.0 | 26.3 | 6.7 | 10.0 | 23.5 | | |
| | | | | | | | | | |

| Type of progression | | | | | | | | |
|---------------------|-------------------------------|----------|------------|--|--|--|--|--|
| cont'd | Distant metast. (1- KM) | NOS (CI) | NOS (1-KM) | | | | | |
| N | 1,181 | 1,230 | 1,230 | | | | | |
| Events | 267 | 337 | 337 | | | | | |
| compet. | | 526 | | | | | | |
| Years | % | % | % | | | | | |
| 0 | 0.0 | 0.0 | 0.0 | | | | | |
| 1 | 10.0 | 18.2 | 19.1 | | | | | |
| 2 | 19.2 | 22.8 | 24.8 | | | | | |
| 3 | 24.9 | 24.3 | 27.1 | | | | | |
| 4 | 26.4 | 25.8 | 29.5 | | | | | |
| 5 | 28.0 | 26.1 | 30.0 | | | | | |
| 6 | 28.6 | 26.9 | 31.5 | | | | | |
| 7 | 29.0 | 27.3 | 32.3 | | | | | |
| 8 | 29.5 | 27.6 | 33.1 | | | | | |
| 9 | 30.6 | 28.1 | 34.2 | | | | | |
| 10 | 30.6 | 28.4 | 34.9 | | | | | |

Table 5b. Time to first progression of patients with other oral and pharynx cancer for period 1998-2020 (N=1,230), also showing the total of progression events (Events) and of deaths as competing risk (compet.).




Figure 5c. Observed post-progression survival of 501 patients with other oral and pharynx cancer diagnosed between 1998 and 2020. These 501 patients with documented progression events during their course of disease represent 40.7 % of the totally 1,230 evaluated cases (incl. M1, n=49, 4.0 %). Patients with cancer relapse documented via death certificates only were excluded (n=247, 20.1 %). Multiple progression types on different sites are included in the evaluation even when not occuring synchronously. The NOS (not otherwise specified) class is included under the condition, that it is the one and only progression type during the course of disease.

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement "not specified" is the only information in registries regarding relapse of the disease. The category "Any type" denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100 % value because patients are potientially considered in more than one subgroup.

| Type of progression | | | | | | | | |
|---------------------|----------|---------------|------------|-----------------------|-------|--|--|--|
| | Any type | Local relapse | Lymph node | Distant metastasis | NOS | | | |
| | n=501 | n=219 | n=79 | n=223 | n=163 | | | |
| Years | % | % | % | % | % | | | |
| 0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | | | |
| 1 | 48.0 | 47.3 | 39.7 | 30.2 | 60.5 | | | |
| 2 | 30.4 | 24.3 | | 15.5 | 44.4 | | | |
| 3 | 24.8 | 18.0 | | 10.9 | 36.7 | | | |
| 4 | 20.6 | 15.7 | | | 31.3 | | | |
| 5 | 17.7 | 15.1 | | | 25.8 | | | |
| 6 | 16.0 | 13.2 | | | 24.2 | | | |
| 7 | 14.1 | | | | 20.9 | | | |
| 8 | 12.0 | | | | 20.0 | | | |
| 9 | 11.3 | | | | 18.3 | | | |
| 10 | 9.1 | | | | | | | |

Table 5d. Observed post-progression survival of patients with other oral and pharynx cancer for period 1998-2020 (N=501).

ICD-10 C14: Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx Observed post-progression survival by period of progression date 1998-2020 % N=223 Period of progression 100 1998-2006 n=68 30.5% 90 2007+ n=155 69.5% 80 70 60 50 40 30 20 10 0 0 1 2 3 5 4 Years

Figure 5e. Observed post-progression (distant metastasis) survival of 223 patients with other oral and pharynx cancer diagnosed between 1998 and 2020 by period of progression.

| Period of progression | | | | | | | | |
|-----------------------|-----------|-------|--|--|--|--|--|--|
| | 1998-2006 | 2007+ | | | | | | |
| | n=68 | n=155 | | | | | | |
| Years | % | % | | | | | | |
| 0 | 100.0 | 100.0 | | | | | | |
| 1 | | 35.1 | | | | | | |
| 2 | | 16.5 | | | | | | |
| | | | | | | | | |

Table 5f. Observed post-progression (distant metastasis) survival of patients with other oral and pharynx cancer for period 1998-2020 by period of progression (N=223).

Shortcuts

| MCR | Munich Cancer Registry, Germany | | | | | | |
|---------------------|---|---|--|--|--|--|--|
| NCI SEER UICC | National Cancer Institute, L Surveillance, Epidemiology Union for International Can | , and End Results, USA | | | | | |
| DCO NA NOS | Death certificate only Not available Not otherwise specified | Death certificate provides the only notification to the registry. | | | | | |
| OS | Overall/Observed survival | Overall/Observed survival (Kaplan-Meier estimate) Date of entry: diagnosis Event: death from any cause | | | | | |
| RS | Relative survival | Survival compared to "general population", ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival | | | | | |
| AS | Assembled survival | Assembled chart of observed, expected, relative survival | | | | | |
| CS | Conditional survival | Survival probability under the condition of surviving a given period of time | | | | | |
| TTP | Time to progression | Time to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression | | | | | |
| | 1-КМ | 1 minus Kaplan-Meier estimator ("inverse" Kaplan-Meier estimator) | | | | | |
| | CI | Cumulative incidence Death as competing risk (according to Kalbfleisch und Prentice) | | | | | |
| PPS | Post-progression survival | Survival since first progression / relapse (Kaplan-Meier estimate) Date of entry (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression Event: death from any cause | | | | | |

Recommended Citation

Munich Cancer Registry. Survival ICD-10 C14: Other oral and pharynx cancer [Internet]. 2022 [updated 2022 Apr 15; cited 2022 Jun 1]. Available from: https://www.tumorregister-muenchen.de/en/facts/surv/sC14_E-ICD-10-C14-Other-oral-and-pharynx-cancer-survival.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.